Phase 2
Completed N=31
Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis
Source: ClinicalTrials.gov NCT00525902 ↗Enrolled (actual)
31
Serious AEs
3.2%
Results posted
Apr 2012
Primary outcomePrimary: Cumulative Endpoint — 21 participants
Summary
The purpose of this study is to assess the safety and efficacy of Adalimumab in uveitis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cumulative Endpoint |
12 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with vision-threatening autoimmune uveitis.
- Failure to respond to prednisone and at least one other systemic immunosuppressive (such as methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, or chlorambucil), or intolerance to such medications due to side effects.
Exclusion Criteria
- Serious concomitant illness that could interfere with the subject's participation in the trial.
- Previous or current use of cyclophosphamide.
- Unable or unwilling to undergo multiple injections.
Data sourced from ClinicalTrials.gov (NCT00525902). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.